DK2185698T3 - Kinaseinhibitorer og anvendelser deraf - Google Patents

Kinaseinhibitorer og anvendelser deraf Download PDF

Info

Publication number
DK2185698T3
DK2185698T3 DK08797416.8T DK08797416T DK2185698T3 DK 2185698 T3 DK2185698 T3 DK 2185698T3 DK 08797416 T DK08797416 T DK 08797416T DK 2185698 T3 DK2185698 T3 DK 2185698T3
Authority
DK
Denmark
Prior art keywords
kinase
peptide
seq
inhibiting
amino acid
Prior art date
Application number
DK08797416.8T
Other languages
English (en)
Inventor
Alyssa Panitch
Brandon Seal
Brian Ward
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of DK2185698T3 publication Critical patent/DK2185698T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (13)

1. Kinaseinhiberende sammensætning, der omfatter et kinaseinhiberende peptid til inhibering af vækst af et neoplasma, hvor det kinaseinhiberende peptid er et peptid med en aminosyresekvens valgt blandt gruppen bestående af HRRIKAWLKKIKALARQLGVAA [SEQ ID NO: 166]; WLRRIKAWLRRIKALARQLGVAA [SEQ ID NO: 113]; WLRRIKAWLRRALARQLGVA [SEQ ID NO: 177]; KAFAKLAARLYRKALARQLGVAA [SEQ ID NO: 173]; FAKLAARLYRKALARQLGVAA [SEQ ID NO: 163]; YARAAARQARAKALARQLGVAA [SEQ ID NO: 106]; YARAAARQARAKALNRQLGVA [SEQ ID NO: 28]; YARAAARQARAKALNRQLAVAA [SEQ ID NO: 100]; og YARAAARQARAKALNRQLAVA [SEQ ID NO: 64],
2. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens HRRIKAWLKKIKALARQLGVAA [SEQ ID NO: 166],
3. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens WLRRIKAWLRRIKALARQLGVAA [SEQ ID NO: 113],
4. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosyresekvens WLRRIKAWLRRALARQLGVA [SEQ ID NO: 177],
5. Kinaseinhiberende sammensætning ifølge krav 1 til anvendelse i en fremgangsmåde til behandling af et neoplasma valgt blandt gruppen bestående af et papillom, et adenom, et hydatidiformmodermærke, et fibrom, et chondrom, et osteom, et leiomyom, et rhabdomyom, et lipom, et hemangiom, et lymphangiom, et polycythaemia vera, en infektiøs mononucleose, et "godartet giiom”, et menin-giom, et ganglioneurom, et neurilemmom, et neurofibrom, et pigmenteret næves (modermærke), et pheochromocytom, en carcinoid tumor, et te ratom, et carei-nom, et adenocarcinom, et basaiceiiecarcinom, et choriocarcinom, et fibrosar-kom, et cbondrosarkom, et osteosarkom, et leiomyosarkom, et rhabdomyosar-kom, et liposarkom, et hemangiosarkom, et lymphangiosarkom, en myeiocytisk leukemi, en erythrocytisk leukemi, en lymphocytisk leukemi, et multipelt myelom, en monocytisk leukemi, et Ewing sarkom, et ondartet non-Hodgkin iymfom, et meduliobiastom, oligodendrogliom, et neurilemmaisarkom, ondartet melanom, thymon, en gliobiastom multiforme, et astrocytom, et ependymom, et meningeal-sarkom, et neuroblastom (schwannom), et neurofibrosarkom, et ondartet pheochromocytom, et retinoblastom, en carcinoid tumor, en nephroblastom (Wilms tumor), et teratocarcinom og et embryonaicarcinom med choriocarcinom.
8. Anvendelse af den kinaseinhiberende sammensætning ifølge krav 1 i fremstillingen af et medikament til behandling af et neoplasma valgt blandt gruppen bestående af et papillom, et adenom, et hydatidiformmodermærke, et fibrom, et chondrom, et osteom, et leiomyom, et rhabdomyom, et lipom, et hemangiom, et lymphangiom, et polycythaemia vera, en infektiøs mononucleose, et "godartet” giiom, et meningiom, et ganglioneurom, et neurilemmom, et neurofibrom, et pigmenteret nævus (modermærke), et pheochromocytom, en carcinoid tumor, et te ratom, et card nom, et adenocarcinom, et basaiceiiecarcinom, et choriocarci-nom, et fibrosarkom, et chondrosarkom, et osteosarkom, et leiomyosarkom, et rhabdomyosarkom, et liposarkom, et hemangiosarkom, et lymphangiosarkom, en myeiocytisk leukemi, en erythrocytisk leukemi, en lymphocytisk leukemi, et multipelt myelom, en monocytisk leukemi, et Ewing sarkom, et ondartet non-Hodgkin Iymfom, et meduliobiastom, oligodendrogliom, et neurilemmaisarkom, ondartet melanom, thymon, en gliobiastom multiforme, et astrocytom, et ependymom, et meningeaisarkom, et neuroblastom (schwannom), et neurofibrosarkom, et ondartet pheochromocytom, et retinoblastom, en carcinoid tumor, en nephroblastom (Wilms tumor), et teratocarcinom og et embryonaicarcinom med choriocarcinom.
7. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhibe-rende peptid er en cyclinafhængig kinaseinhibitor.
8. Kinaseinhiberende sammensætning ifølge krav 1, hvor sammensætningen inducerer programmeret celledød af mindst en celle i en cellepopulation.
9. Kinaseinhiberende sammensætning ifølge krav 1, hvor sammensætningen inhiberer hyperplasi af mindst en hyperplastisk celle i en cellepopulation.
10. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens KAFAKLAARLYRKALARQLGVAA [SEQ ID NO: 173],
11. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens FAKLAARLYRKALARQLGVAA [SEQ ID NO: 163],
12. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALARQLGVAA [SEQ ID NO: 106],
13. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLGVA [SEQ ID NO: 28].
14. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhiberende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLAVAA [SEQ ID NO: 100],
15. Kinaseinhiberende sammensætning ifølge krav 1, hvor det kinaseinhibe-rende peptid til inhibering af vækst af et neoplasma er et peptid med en aminosy-resekvens YARAAARQARAKALNRQLAVA [SEQ ID NO: 64],
DK08797416.8T 2007-08-07 2008-08-07 Kinaseinhibitorer og anvendelser deraf DK2185698T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96394107P 2007-08-07 2007-08-07
US99497007P 2007-09-24 2007-09-24
PCT/US2008/072525 WO2009021137A2 (en) 2007-08-07 2008-08-07 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DK2185698T3 true DK2185698T3 (da) 2015-07-27

Family

ID=40342047

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08797416.8T DK2185698T3 (da) 2007-08-07 2008-08-07 Kinaseinhibitorer og anvendelser deraf

Country Status (6)

Country Link
US (2) US8741849B2 (da)
EP (1) EP2185698B1 (da)
JP (1) JP5703466B2 (da)
DK (1) DK2185698T3 (da)
ES (1) ES2547229T3 (da)
WO (1) WO2009021137A2 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2155228T3 (da) * 2007-01-10 2014-07-07 Purdue Research Foundation Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
KR20170001756A (ko) * 2008-10-20 2017-01-04 모레 매트릭스 인코포레이티드 유착 치료 또는 예방용 폴리펩티드
AU2013202108B2 (en) * 2008-12-10 2015-12-24 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
AU2009324661A1 (en) * 2008-12-10 2011-07-07 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US8530429B2 (en) * 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
SG194135A1 (en) 2011-04-12 2013-11-29 Matrix Inc Moerae Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN102949722A (zh) * 2011-08-26 2013-03-06 中国医学科学院放射医学研究所 基于p38抑制剂和细胞生长因子的新颖药物组合物
EP2771069A4 (en) 2011-10-27 2015-08-26 Mayo Foundation INHIBITION OF G-PROTEIN-COUPLED RECEPTOR-6-KINASE POLYPEPTIDE
EP2773777B1 (en) * 2011-10-31 2020-05-13 University of Utah Research Foundation Genetic alterations in glioblastoma
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2014160364A1 (en) * 2013-03-13 2014-10-02 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
WO2014169256A2 (en) * 2013-04-11 2014-10-16 Vanderbilt University Polyplexes
GB201314610D0 (en) * 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
WO2015057461A2 (en) 2013-10-18 2015-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
CN103739678B (zh) * 2013-12-31 2015-09-02 刘培臣 抑制粘附斑激酶多肽及其应用
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US9902739B2 (en) 2014-04-21 2018-02-27 Mayo Foundation For Medical Education And Research Small molecule inhibitors of G protein coupled receptor 6 kinases polypeptides
EP3145543A4 (en) 2014-05-23 2017-12-13 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
AU2015300966A1 (en) * 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
US10512651B2 (en) * 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
KR20170083063A (ko) 2014-11-17 2017-07-17 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
US10087225B2 (en) 2015-01-08 2018-10-02 Moerae Matrix, Inc. Formulation of MK2 inhibitor peptides
RU2017135072A (ru) 2015-03-12 2019-04-10 Мори Матрикс, Инк. Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
US11091472B2 (en) 2016-02-26 2021-08-17 The Regents Of The University Of California PI-kinase inhibitors with anti-infective activity
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US11213857B2 (en) 2017-06-06 2022-01-04 Derrick Corporation Method and apparatus for screening
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3794014A4 (en) 2018-05-15 2022-03-16 InterK Peptide Therapeutics Limited PEPTIDE ACTIVATING AGENT
CA3100072A1 (en) * 2018-05-15 2019-11-21 Interk Peptide Therapeutics Limited Activating agents
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
JP7474752B2 (ja) * 2018-09-12 2024-04-25 パデュー リサーチ ファウンデイション キナーゼ阻害剤としてのアルキニルニコチンアミド化合物
EP3908577A4 (en) * 2019-01-11 2022-06-29 The Board of Trustees of the Leland Stanford Junior University Pi4-kinase inhibitors with anti-cancer activity
EP3941909A4 (en) 2019-03-21 2023-01-25 The Board Of Trustees Of The Leland Stanford Junior University Pi4-kinase inhibitors and methods of using the same
WO2021097407A2 (en) * 2019-11-15 2021-05-20 Regents Of The University Of Colorado, A Body Corporate Novel peptide compositions and methods of treating neurological injury
CN114605497B (zh) * 2021-02-10 2023-04-28 北京欣安诚科技有限公司 一种dapk1磷酸化底物的人工小分子干扰肽及其制药用途
CN115976033B (zh) * 2022-12-14 2024-05-17 西南大学 瓜实蝇tssk1和tssk3基因及其应用
WO2025151669A1 (en) * 2024-01-10 2025-07-17 President And Fellows Of Harvard College Clk2 inhibition as a radiation countermeasure

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) * 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) * 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) * 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
NL192564C (nl) * 1982-10-08 1997-10-03 Glaxo Group Ltd Inrichting voor het toedienen van medicamenten aan patiënten.
EP0211595B1 (en) * 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
EP0544671A4 (en) * 1990-04-18 1993-09-15 The University Of Utah Colonic-targeted oral drug-dosage forms based on crosslinked hydrogels containing azobonds and exhibiting ph-dependent swelling
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
CN1048254C (zh) * 1993-12-09 2000-01-12 托马斯杰弗逊大学 用于将预定的改变引入靶基因中的化合物
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
US6291527B1 (en) * 1998-04-11 2001-09-18 Errekappa Euroterapici S.P.A. Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7615373B2 (en) * 1999-02-25 2009-11-10 Virginia Commonwealth University Intellectual Property Foundation Electroprocessed collagen and tissue engineering
US20020009491A1 (en) * 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP2004520088A (ja) * 2000-08-15 2004-07-08 サーモディックス，インコーポレイティド 薬剤混和マトリックス
JP2004522742A (ja) * 2000-12-08 2004-07-29 ベイラー　カレッジ　オブ　メディシン 免疫応答の改変において使用するためのｔｒｅｍ−１スプライス改変体
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
DE10118774A1 (de) 2001-04-17 2002-10-31 Jerini Ag Verfahren zur Bestimmung der Substratspezifität einer enzymatischen Aktivität und Vorrichtung hierzu
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7135453B2 (en) * 2001-08-23 2006-11-14 Arizona Board Of Regents Reagents and methods for smooth muscle therapies
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
US20050153372A1 (en) * 2002-02-21 2005-07-14 Paul Greengard Compositions and method for regulation of calcium-dependent signaling in brain
US20040005686A1 (en) 2002-03-07 2004-01-08 Pharmacia Corporation Crystalline structure of human MAPKAP kinase-2
WO2003084481A2 (en) * 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
JP2006515159A (ja) 2002-08-02 2006-05-25 ワイエス Ｍｋ２相互作用タンパク質
AU2003297431A1 (en) 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
ES2268631T3 (es) 2003-02-21 2007-03-16 Arizona Board Of Regents Utilizacion de hsp20 para estimular la cicatrizacion de heridas y/o para reducir la formacion de cicatrices.
IL156429A0 (en) 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
AU2004281838B2 (en) * 2003-10-17 2008-01-31 Arizona Board Of Regents Novel heat shock protein 20-related polypeptides and uses therefor
ATE427499T1 (de) 2004-05-21 2009-04-15 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
WO2006132647A2 (en) * 2004-07-23 2006-12-14 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
JP2008519861A (ja) * 2004-11-12 2008-06-12 マサチューセッツ・インスティテュート・オブ・テクノロジー 細胞増殖性疾患を治療するための方法および組成物
EP1824336A4 (en) 2004-12-02 2009-10-14 Univ North Carolina INHIBITION OF PHOSPHORYLATION HSP27 TO TREAT VESICATION DISORDERS
WO2006105278A2 (en) * 2005-03-29 2006-10-05 The Regents Of The University Of California Controlling stem cell destiny destiny with tunable network
EP1868629B1 (en) * 2005-04-15 2014-10-22 Arizona Biomedical Research Commission Therapeutic fusion peptides for the treatment of metastatic cancer
SI1948259T1 (sl) * 2005-10-26 2017-07-31 Genesis Technologies Limited Acelularni bioabsorbljivi tkivni regeneracijski matriksi, proizvedeni z inkubiranjem acelularnih proizvodov krvi
JP2009513158A (ja) * 2005-11-01 2009-04-02 アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティ 新規タンパク質伝達ドメインおよびその使用
WO2007062060A2 (en) * 2005-11-22 2007-05-31 Ted Reid Methods and compositions using substance p to promote wound healing
JP5048772B2 (ja) 2006-07-12 2012-10-17 ジ アリゾナ ボード オブ レジェンツ，ア ボディ コーポレイト アクティング フォア アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティ 線維性疾患及びケロイドを治療及び抑制する方法
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
DK2155228T3 (da) 2007-01-10 2014-07-07 Purdue Research Foundation Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
JP5703466B2 (ja) 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
WO2009123759A2 (en) 2008-04-02 2009-10-08 Moerae Matrix, Inc. Therapeutic uses of biocompatible biogel compositions
KR20170001756A (ko) 2008-10-20 2017-01-04 모레 매트릭스 인코포레이티드 유착 치료 또는 예방용 폴리펩티드
AU2009324661A1 (en) 2008-12-10 2011-07-07 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) * 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
SG194135A1 (en) 2011-04-12 2013-11-29 Matrix Inc Moerae Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Also Published As

Publication number Publication date
WO2009021137A3 (en) 2009-07-09
EP2185698B1 (en) 2015-04-22
JP5703466B2 (ja) 2015-04-22
US20140342993A1 (en) 2014-11-20
ES2547229T3 (es) 2015-10-02
EP2185698A4 (en) 2012-03-28
US8741849B2 (en) 2014-06-03
JP2010535508A (ja) 2010-11-25
WO2009021137A2 (en) 2009-02-12
US9447158B2 (en) 2016-09-20
HK1144306A1 (zh) 2011-02-11
US20130184221A9 (en) 2013-07-18
US20090149389A1 (en) 2009-06-11
EP2185698A2 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
US9447158B2 (en) Kinase inhibitors and uses thereof
US9327008B2 (en) Cell-permeant peptide-based inhibitor of kinases
Jobson et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
US7157422B2 (en) Glycogen synthase kinase-3 inhibitors
WO2011160016A2 (en) E3 binding pockets and identification and use of e3 ligase inhibitors
Goel et al. The unique N‐terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1
ES2252928T3 (es) Genes y proteinas ciclina e1.
US20240083948A1 (en) Modified peptides and associated methods of use
CA2811086C (en) Step-derived peptide for brain injury treatment
HK1144306B (en) Kinase inhibitors and uses thereof
US6641994B2 (en) Methods of identifying anti-viral agents
AU2013202108B2 (en) Cell-permeant peptide-based inhibitor of kinases
AU2016201861B2 (en) Cell-permeant peptide-based inhibitor of kinases
US20240165113A1 (en) Methods of treatment for leukemia
JP4273232B2 (ja) サイクリン依存性キナーゼ５（Ｃｄｋ５）特異的ペプチド性阻害剤
HK1163449A (en) Cell-permeant peptide-based inhibitor of kinases
CN117957239A (zh) 癌症治疗剂
WO2006001275A1 (ja) グリコーゲン合成酵素を直接活性化する化合物をスクリーニングする方法
US20060084600A1 (en) Human homologues of fused gene
US20040121463A1 (en) Methods and compositions for modulating apoptosis